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ABSTRACT: Circadian clocks, biological timekeepers that are
present in almost every cell of our body, are complex systems
whose disruption is connected to various diseases. Controlling
cellular clock function with high temporal resolution in an
inducible manner would yield an innovative approach for the
circadian rhythm regulation. In the present study, we present
structure-guided incorporation of photoremovable protecting
groups into a circadian clock modiﬁer, longdaysin, which inhibits
casein kinase I (CKI). Using photodeprotection by UV or visible
light (400 nm) as the external stimulus, we have achieved
quantitative and light-inducible control over the CKI activity
accompanied by an accurate regulation of circadian period in
cultured human cells and mouse tissues, as well as in living zebraﬁsh. This research paves the way for the application of
photodosing in achieving precise temporal control over the biological timing and opens the door for chronophotopharmacology
to deeper understand the circadian clock system.
■ INTRODUCTION
Circadian clocks are self-sustaining, feedback loop-based
biochemical oscillators that regulate rhythmic aspects of
behavior and physiology.1 Through these oscillators, biological
processes are synchronized with the daily environmental
changes caused by the rotation of the Earth around the Sun.
Keeping all of the cellular circadian clocks perfectly
synchronized within one organism is crucial for its normal
and healthy functioning. It has been shown that disruption of
circadian clock function promotes a wide variety of illnesses,
such as Alzheimer’s, cardiovascular, gastrointestinal, psycho-
logical, and other diseases.2,3 As suggested previously,3 there
are three major strategies in treating circadian rhythm
disorders: optimizing the circadian lifestyle (“training the
clock”), optimizing timing of therapies (“clocking the drugs”),
and targeting speciﬁc circadian clock components (“drugging
the clock”).
The crucial role of the circadian clocks in health and disease
led to the emergence of strategies to control their function with
small molecules.4 Chemical screening, based on cell-based
circadian assays with luminescent readout, has been extensively
used in discovery of small molecule modiﬁers of the circadian
clock.5−10 Alongside chemical screening, synthetic approaches
have emerged as methods for development and optimization of
small molecules that are used as a powerful tool for better
understanding of clock regulation.11−16 Despite breakthroughs
in developing such clock modiﬁers, achieving exact, externally
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regulated time-control poses a general challenge for both in
vitro and in vivo systems. Enabling ﬁne temporal control by
means of clock modiﬁers over the circadian rhythm will
enhance their utility in the investigation of the underlying
clock regulation mechanisms as well as their therapeutic
application.
The application of photoremovable protecting groups (PPG;
also known as photocages or photocleavable groups) is an
attractive approach to achieve precise regulation of bioactivity
that is employed in photopharmacology.17,18 This emerging
ﬁeld of chemical biology relies on the use of light as an ideal
external stimulus that oﬀers high spatiotemporal resolution and
bioorthogonality without causing any contamination in
comparison to the other stimuli, such as pH and redox
changes, metal addition, etc.19 Furthermore, having control
over properties of light allows precise control over release or
activation of a drug,20,21 which is an ideal solution for
obtaining a ﬁne modulation over circadian time of biological
clocks and has been employed in other oscillating systems.22
The intrinsic period of the circadian rhythm is modulated by
posttranslational modiﬁcations.23 The enzyme casein kinase I
(CKI) is a clock regulatory kinase, known to play a crucial role
in determining the speed of the circadian rhythm. CKI
phosphorylates the period (PER) protein and promotes its
degradation through a proteasomal pathway.24,25 Genetic
mutations of CKI-dependent phosphorylation site of PER2
and CKIδ, an isoform of CKI, lead to the “familial advanced
sleep phase” caused by shortening of the circadian period.26,27
The key role of CKI in establishing the period length has also
been demonstrated pharmacologically, where CKI inhibitors,
such as longdaysin,5 drastically lengthen the period.6,7,28−30
Here, we present quantitative and inducible control of the
cellular circadian time by a photopharmacological approach
using photocaged longdaysin, a purine-based inhibitor of CKIα
and CKIδ that shows a strong period lengthening eﬀect. We
have designed photocleavable derivatives DK325 and DK359
for a light-dependent control of CKI activity, which enabled
the regulation of the circadian period in human U2OS cells,
mouse tissue explants, and zebraﬁsh, by choosing the
wavelength and duration of light irradiation.
■ RESULTS
Design of the Caged Longdaysin. Our photopharmaco-
logical approach utilizes photoremovable protecting groups
(PPGs), which upon incorporation into the structure of
bioactive compounds are able to either fully deactivate or
signiﬁcantly suppress their potency and enable the release of
the active molecule by light illumination (Figure 1A).21,31,32 In
order to reversibly suppress the activity of longdaysin by
rationally designed incorporation of a PPG, it was necessary to
recognize the most important binding interaction of longdaysin
with CKI. Since a cocrystal structure of CKI−longdaysin
complex was not reported, we performed molecular docking
simulations. The study revealed crucial interactions of
longdaysin with the hinge region of CKIα and CKIδ, forming
two hydrogen bonds (Figure 1B). This interaction with the
hinge region has also been observed in ADP binding (e.g.,
PDB entry 5X17),33 indicating a competitive inhibition
mechanism of longdaysin. Based on this observation, we
targeted the secondary amine at the C6 carbon of the purine
scaﬀold, which formed a hydrogen bond with Leu93 backbone
(Figure 1B) for incorporation of a PPG to eﬃciently disrupt
the interaction between longdaysin and CKIα/δ. Thus, two
molecules (DK325 and DK359) were designed by incorporat-
ing 2-nitrobenzyl and NVOC (6-nitroveratryloxycarbonyl)
PPGs, respectively, at this position (Figure 2A).
To predict the diﬀerences in potential CKI interactions
among longdaysin, DK325, and DK359, molecular docking
simulations were performed (Figures 1B and S1). In terms of
protein−ligand interaction energies, longdaysin docking
conformations ranked signiﬁcantly lower than DK325 and
DK359 in CKIα and CKIδ (Figures 1B and S1). Moreover,
while longdaysin conformations were predominantly found at
the hinge region forming multiple hydrogen bonds with the
Leu93 backbone, DK325 and DK359 were placed more
diﬀusely in the adjacent cavity formed by the P-loop in CKIα
and CKIδ. No hinge region interactions were observed for
DK325 and DK359 in CKIα. The scarcity of prominent
interactions and steric ﬁt of DK325 and DK359 with the
proteins and the less favorable protein−ligand interaction
energies (indicated by higher docking scores) suggested
severely reduced binding of DK325 and DK359 with CKI.
With the molecular-docking-inspired design of the PPG−
longdaysin in hand, we used our previously published
strategy34 to develop an eﬃcient two-step synthetic route to
produce diﬀerently protected longdaysin analogues (Support-
ing Information). For DK325, we employed 2-nitrobenzyl
group (Figure 2A), which belongs to a class of widely applied
photocleavable groups introduced by Barltrop et al. in 1966.35
Generally, this class of PPGs can be removed under irradiation
with UV light. For DK359, the two methoxy groups in the 6-
nitroveratryloxycarbonyl (NVOC) derivative were introduced
to induce a bathochromic shift of the absorption spectrum that
improves the photochemical properties, such as the wavelength
Figure 1. General scheme of the photocleavable approach and
putative binding mode of CK1α-longdaysin complex. (A) Schematic
representation of the photocleavage approach, where light is used to
remove the photoremovable protecting group (PPG) for the release
of an active compound. (B) Ligand-binding site of CKIα is
characterized by a hinge region (green) and an adjacent cavity
formed by the P-loop (yellow area; gray represents P-loop). Docking
simulations indicated interaction of the purine scaﬀold of longdaysin
with the hinge region (two hydrogen bonds with Leu93 backbone,
indicated by yellow line) (glide XP docking score: −7.39 kcal/mol).
The table provides mean estimated ligand binding free energies from
molecular docking simulations of longdaysin, DK325, and DK359
with CKIα and CKIδ. SD = standard deviation.
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required for photocleavage, as well as photodeprotection
eﬃciency.31,36,37 These two PPGs are structurally small and do
not signiﬁcantly interfere with the water solubility provided by
the purine core (50−60 μM).
Photochemical Properties of the Caged Longdaysin.
Photochemical properties of the protected longdaysin
derivatives were assessed by means of UV−vis absorption
spectroscopy (Figure 2B) and ultraperformance liquid
chromatography mass spectrometry (UPLC−MS; Figures
2C,D). The photocleavage process in DMSO and kinase
assay buﬀer was monitored by UV−vis spectrometry, which
showed clear isosbestic points for both DK325 and DK359,
indicating single product formation (Figures 2B and S2). UV
light was used for photocleavage of DK325, while 400 nm light
was applied for DK359 due to an extended absorption in
visible region as the result of additional methoxy groups
(Figure S3A). Furthermore, the photocleavage in kinase assay
buﬀer and cellular assay medium was examined to make an
unambiguous comparison between photocleavage and bio-
logical activity. The deprotection rate of DK359 was faster
than that of DK325 in kinase assay buﬀer under the same 365
nm light irradiation conditions, i.e., lamp distance and photon
ﬂux (Figures 2C and S3). Using chemical actinometry, the
quantum yields (Φ365 nm) of the photocleavable reaction were
determined to be 0.22 for both compounds (Figure S4).
Despite the same quantum yield, faster deprotection rate of
DK359 can be explained by much higher extinction coeﬃcient
at 365 nm (Figure S5). The photodeprotection was also
performed in the cellular assay medium that contains luciferin,
a compound that absorbs light signiﬁcantly at λ = 365 nm
(Figures 2D, S3A, and S6). Since luciferin largely reduced
photodeprotection eﬃciency of UV light, we applied 400 nm
light, which surprisingly cleaved both compounds despite very
low extinction coeﬃcients of DK325 at this wavelength (Figure
S3A). Whereas longdaysin release from DK325 was slower
(Figure 2D, left panel; Figure S3B right panel), DK359 showed
nearly full deprotection after 30−60 min of irradiation (Figure
2D, right panel; Figure S3C right panel).
The Photodosing of CKI Inhibition. Furthermore, we
attempted the light-dependent control of CKI activity in vitro.
The photocleavage of DK325 and DK359 was induced by UV
and violet light irradiation during the assay with diﬀerent
irradiation times (Figure 3A) in order to analyze the
correlation between light dosimetry and CKIα inhibition
level. The starting concentration of DK325 and DK359 was 40
μM, which was 7 times higher than the IC50 value of
longdaysin (5.6 μM).5 DK325 and DK359 did not show kinase
inhibition under the dark conditions (Figure 3B,C, 0 min
irradiation). This result validates our rational molecular design
that aimed at preventing the interactions with CKI by the
incorporation of PPGs on the secondary amine (Figure 1B).
Upon increase of irradiation time (UV light in Figure 3B; 400
Figure 2. Photodeprotection studies of DK325 and DK359. (A) Photodeprotection of DK325 and DK359 using UV (λ = 365 nm) and violet light
(λ = 400 nm). (B) UV−vis spectroscopy analysis of photodeprotection of DK325 and DK359 (40 μM in DMSO, 30 °C) showing clear isosbestic
points upon irradiation of DK325 with UV light and DK359 with 400 nm light. (C) UPLC traces for monitoring the deprotection of DK325 (left)
and DK359 (right) (40 μM in CKI assay buﬀer) with UV light. Retention time (min) is shown on the x-axis. Shown are the peaks of longdaysin
(11.95 min, black box), DK325 (14.49 min, purple box), and DK359 (14.11 min, blue box). (D) UPLC traces for monitoring the deprotection of
DK325 (left) and DK359 (right) (40 μM in cellular assay medium) with 400 nm light. Retention time (min) is shown on the x-axis. Shown are the
peaks of longdaysin (11.95 min, black box), DK325 (14.49 min, purple box), and DK359 (14.11 min, blue box).
Journal of the American Chemical Society Article
DOI: 10.1021/jacs.9b05445
J. Am. Chem. Soc. 2019, 141, 15784−15791
15786
nm light in Figure 3C), the activity of CKIα was reduced in a
dose-dependent manner, reaching the maximum level of
inhibition after approximately 30 min for DK325 and 10 min
for DK359. As a control, irradiation with UV or 400 nm light
during the 60 min period in the absence of compounds did not
aﬀect the kinase activity (Figure 3D). These results are in
perfect correlation with the UPLC analysis, which showed
more eﬃcient uncaging of DK359 than DK325 under the same
conditionslight and distance (Figures 2C and S3). The
minimal activity of CKIα reached is around 40%. DK359 also
repressed the activity of CKIδ, and the minimal activity
reached was 29% upon irradiation with 400 nm (Figure S7).
This indicates a gradual release of longdaysin over the
irradiation time allowing CKIα and CKIδ to consume ATP
before the whole amount of DK325 or DK359 was
photodeprotected. These results demonstrate tuning of CKIα
and CKIδ activity by light.
Inducible Period Control of the Circadian Clock by
Photodosing in Human U2OS Cells. Next, we tried to
control cellular circadian rhythms by targeting CKI proteins
inside the cells (cytosol and nucleus) with photodosing. The
experiments were designed to release longdaysin in highly
controlled manner by tuning wavelength as well as the
irradiation duration of light applied to the cells. This allowed
us to analyze whether cellular time changes are dependent on
properties of the applied light. The experiments were
conducted using the bioluminescent circadian assay in
human U2OS cells with a Bmal1-dLuc reporter that consists
of Bmal1 gene promoter followed by coding sequence of
destabilized luciferase.28 We treated the cells with various
concentrations of DK325 and DK359 (six points of the 3-fold
dilution series), as well as diﬀerent irradiation durations (0−30
min), and then measured luminescence rhythms. Period
parameter represents time required for the circadian clock to
run one cycle and was determined from luminescence rhythms
by curve ﬁtting. Longdaysin lengthened the period as reported
previously,5 and the eﬀect was independent of UV light
irradiation (Figure 4A, purple lines). In agreement with the
Figure 3. Inhibition of CK1α in a light-dependent manner. (A)
Compounds DK325 and DK359 (40 μM ﬁnal concentration) were
applied to CKIα-reaction mixture. The release of longdaysin was
controlled by diﬀerent irradiation duration (0−60 min) after the
reaction was initiated by the addition of ATP and peptide substrate.
(B and C) In situ irradiation results. Degree of CK1α inhibition was
plotted against irradiation time of UV light, λ = 365 nm (B) and with
visible light, λ = 400 nm (C). ATP consumption in DMSO control
samples, containing the enzyme and peptide substrate without
inhibitor, was set at 100% enzyme activity. (D) Eﬀects of 1 h light
irradiation on CKIα activity. Showing a nonirradiated (black), UV-
light-irradiated (red; λ = 365 nm) and visible light-irradiated (blue, λ
= 400 nm) samples. Results are mean ± SD (n = 2) (B−D).
Figure 4. Irradiation-dependent eﬀects of DK325 and DK359 on
circadian rhythms in human U2OS cells. (A) Eﬀect of UV light.
Bmal1-dLuc reporter cells were treated with various concentrations of
compound (six points of 3-fold dilution series in DMSO) and
irradiated with 365 nm light for 0−30 min. Luminescence rhythms
were then monitored (the left panel, mean of n = 4). Rhythms of
DMSO and longdaysin controls are also shown. Period changes
compared to a DMSO control are plotted in the right panels (n = 4);
p values are summarized in Table S1. (B, C) Eﬀect of visible light (λ =
400 nm). Bmal1-dLuc reporter cells were treated with compounds and
irradiated with 400 nm light for 0−30 min at the beginning (B) or in
the middle (C, indicated by arrows) of luminescence monitoring. In
(C), period changes pre- and postirradiation are plotted in the top
right and bottom right panels, respectively.
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kinase assay, both DK325 and DK359 exhibited almost no
eﬀect on circadian period in the dark, indicating that the
potent period eﬀect of longdaysin was successfully suppressed
by incorporation of 2-nitrobenzyl and NVOC groups also in
cell culture conditions. DK325-treated cells exhibited 3−4 h
period lengthening by 30 min UV light irradiation, while
DK359-treated cells showed this period lengthening in less
than 10 min irradiation (Figure 4A). Moreover, the longest
irradiation (30 min) in case of DK359 was able to slow the
cellular clock period by 10 h.
Using visible light instead of UV light has multiple
advantages in photopharmacology, including deeper tissue
penetration and lower cytotoxicity.38 For both compounds, a
shorter irradiation time was required for period lengthening by
400 nm light compared with UV light, and the potency was
enhanced (Figure 4B). This eﬀect is presumably due to a high
concentration of luciferin (0.2 mM) in the cell culture
medium. Luciferin has a signiﬁcant absorption at 365 nm
and thus can interfere upon photodeprotection with UV light,
while its absorption at 400 nm is negligible and enables better
eﬃciency of visible light (Figures S3A and S6). Also, to
conﬁrm that the photodeprotection side products have no
eﬀect on the circadian period modulation, we designed
photocaged acetate with 2-nitrobenzyl (DK491) and NVOC
(DK492) groups (Figure S8A). Photodeprotection of these
compounds releases acetate and the same side products as
DK325 and DK359. Cells treated with DK491 and DK492 did
not show period change upon irradiation with both wave-
lengths (Figures S8B and S8C), conﬁrming that eﬀect from
DK325 and DK359 originates only from the release of
longdaysin. With these irradiation experiments, we showed that
it is possible to adjust cellular circadian period with high
temporal precision using light as a privileged external stimulus.
We further tried to control pre-existing rhythms 3 days after
the addition of the compounds (Figure 4C) in order to
examine the cellular stability of photocaged molecules and
conﬁrm light-initiated modulation of circadian period. The
cells were treated with compounds, and then luminescence
rhythms were measured without light irradiation. Before
irradiation, DK325 and DK359 showed almost no eﬀect on
the period (“pre”, Figure 4C, right top panels). On the third
day, the cells were exposed to visible light (λ = 400 nm) for 0−
30 min, and the luminescence rhythms were monitored for
three more days (“post”, Figure 4C, right bottom panels).
Interestingly, the period lengthening eﬀects were much
stronger than those observed with irradiation from the
beginning (Figure 4B), possibly due to increased cellular
concentration of the compounds during three-day incubation.
These results conﬁrm high stability of DK325 and DK359 in
the cellular medium with cells present and light-induced
uncaging during the assay.
Ex Vivo Manipulation of the Circadian Period by
Light in Mouse Tissues. Following experiments in cells, we
tested the principle of light-dependent period control at the
tissue level using spleen explant of Per2::Luc knock-in reporter
mice (Figure 5). The mice express PER2-luciferase fusion
protein under control of the endogenous Per2 promoter.39
According to rhythmic activation of the Per2 promoter, the
tissue explants show circadian changes of luminescence
intensity (Figure 5A, gray line). The explants were treated
with compounds and irradiated with 400 nm light, and then
luminescence rhythms were measured. Consistent with the
cellular assay results, DK325 and DK359 showed period
lengthening in a concentration- and irradiation-duration-
dependent manner with a stronger eﬀect of DK359 in
comparison to DK325, while 400 nm light showed no
inﬂuence on the eﬀect of longdaysin (Figure 5A−D). In
addition to the peripheral clock in spleen, we investigated the
eﬀect of DK359 on the central clock in the hypothalamic
suprachiasmatic nucleus (SCN) that controls behavioral
rhythms. The compound showed no eﬀect in the dark and
induced period lengthening upon 400 nm light irradiation
(Figure 5E,F). Together, DK359 enabled light-dependent
quantitative and inducible control of the circadian period at
both cellular and tissue levels.
In Vivo Manipulation of the Circadian Period by
Light. In addition to mouse tissue explant, we tested living
zebraﬁsh larva containing the Per3:Luc reporter for circadian
activity monitoring. Previous results showed that the larva
circadian rhythms exhibit a sensitivity to longdaysin for period
lengthening similar to human cell lines.5 The larvae were
exposed to four cycles of light/dark cycles and transferred to
constant darkness for circadian monitoring. The DK359
treatment were performed 6 h following the start of the
Figure 5. Irradiation-dependent eﬀects of DK325 and DK359 on
circadian rhythms in mouse tissue explants. Spleen tissue (A−D) and
the SCN (E−G) of the Per2::Luc knock-in reporter mice were treated
with various concentrations of compound and irradiated with λ = 400
nm light for 0−30 min. Luminescence rhythms were then monitored
and shown in (A) and (B) (mean of n = 3−4) and in (E) and (F)
(representative result). Period changes compared to a DMSO control
are plotted in (C) for concentration-dependent period lengthening, in
(D) for irradiation-duration-dependent period lengthening (n = 2−4),
and in (G) for the SCN (n = 2). ****p < 0.0001, **p < 0.01, *p <
0.05 against the dark control.
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circadian time (CT6) and immediately followed by 400 nm
light treatment (0−10 min). In the absence of DK359 (DMSO
control), a short 400 nm light treatment at CT6 did not aﬀect
the phase and period of the luminescence rhythms despite
every cell being light sensitive in this organism (Figure 6A). In
the presence of DK359, the period was substantially
lengthened in an irradiation-duration-dependent manner
(Figure 6B). The shorter irradiation time needed for zebraﬁsh
in vivo in comparison to cell and tissue culture experiments can
be explained by lack of vitamins, FBS, and other light-
absorbing components in solution for zebraﬁsh maintenance.
■ DISCUSSION
Kinases play an important role in a wide variety of
diseases,40−42 thus being one of the most interesting
pharmaceutical targets.43 In the circadian clock function,
kinases are also essential regulators in every cell throughout the
body.23 To enable inducible regulation of clock function via
kinase activity control, the eﬀect of longdaysin, a circadian
modulator inhibiting casein kinase I (CKIα and CKIδ), was
silenced with PPGs. This has enabled the reactivation of
silenced longdaysin by light irradiation with high temporal
control, allowing for conditional modulation of the circadian
rhythm with light, from the enzymatic level to a living
organism.
On the basis of the rational molecular design, facilitated by
molecular docking, photocleavable groups (2-nitrobenzyl and
NVOC) were incorporated at the 6-NH position of long-
daysin, which is crucial for the interaction with the hinge
region of CKIα and CKIδ. As a result, CKI inhibitory activity
of protected longdaysin was entirely suppressed. This approach
features several advantages. First, a straightforward two-step
synthesis of the modulators was established that emphasizes
the generality of this approach, which may potentially allow for
incorporation of red-shifted PPGs31,44−46 that would facilitate
low energy and deeper tissue penetrating light. Furthermore,
the water solubility of longdaysin was not compromised by
introducing small and rather polar PPGs. Finally, photo-
chemical properties showed quantitative photodeprotection of
both modulators. DK359 exhibited much faster deprotection
under the same irradiation conditions that makes it more
suitable for a quick period adjustment. The circadian period
was successfully modiﬁed by using both UV and visible light
(400 nm) by exploring variable concentration and photodose.
A ﬁne and conditional tuning of the period length in cellulo, ex
vivo, and in zebraﬁsh was achieved within (sub)minute range
of light irradiation, which presents an ideal system for further
mechanistic and in vivo studies.
So far, the common mechanism of the circadian clock in
each cell of the body prevented the use of clock modiﬁers in
precise spatiotemporal control. As a result of the suppressed
activity of protected longdaysin toward CKI and period
lengthening, we believe that our approach will be applicable
also to control tissue-speciﬁc clocks with spatial resolution
limited only by the ability of light delivery. Therefore, future
research should focus on formulation and development of the
photocaged derivatives that enable spatially controlled
activation. Together with our work on temporally controlled
regulation, this will enable us to study the circadian
organization in mammals, to identify the relationship between
clock disruption and disease development, as well as to study
the potential use of this chronophotopharmacology approach
in chronotherapy in the future.
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Figure 6. Irradiation-dependent eﬀects of DK359 on circadian
rhythms in zebraﬁsh larva. (A) Per3::Luc zebraﬁsh larvae were treated
with compound DK359 (4 μM) or DMSO at CT6 and irradiated with
λ = 400 nm light for 0 and 10 min. Luminescence rhythms were then
monitored for 3 d (mean of n = 3). Data are baseline subtracted for
detrending. (B) Period changes compared to a DMSO control for 0,
3, 5, and 10 min light exposure are plotted (n = 13−15). ****p <
0.0001, ***p < 0.001, **p < 0.01, *p < 0.05 against the dark control.
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